Johnson & Johnson's CAPLYTA (lumateperone) showed superior efficacy and favorable safety in major depressive disorder in a new network meta-analysis. The study compared CAPLYTA to other FDA approved antipsychotics used as adjunctive treatment for major depressive disorder. Results were presented at a major neuroscience meeting, highlighting comparative effectiveness and tolerability versus competing therapies. For investors tracking NYSE:JNJ, this update on CAPLYTA arrives with the stock at...